文献速递肿瘤 PET/CT核素与放射性配体治疗

基线FDG与PSMA PET/CT复合评分对177Lu-PSMA治疗资格的预后价值

Prognostic Value of a Composite Score Incorporating Baseline [18F]FDG PET/CT and [68Ga]Ga-PSMA-11 PET/CT When Screening for [177Lu]Lu-PSMA Treatment Eligibility (PROFILE Study).
PubMed 文献 · J Nucl Med · 2026-10-01

本研究为多中心回顾性研究,纳入174例接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者,基于基线[18F]FDG PET/CT和[68Ga]Ga-PSMA-11 PET/CT等参数构建PROFILE预后评分,将患者分为低、中、高危三组,中位总生存分别为17.2、13.0、8.6个月(P<0.0001),并在114例独立验证队列中证实。

要点

  • PROFILE评分包含5项独立不良预后因素,可对mCRPC患者进行风险分层。
  • 开发队列低、中、高危组中位OS分别为17.2、13.0、8.6个月(P<0.0001)。
  • 验证队列低、中、高危组中位OS分别为20.4、14.3、8.8个月(P<0.0001)。

核心结论

  • PROFILE评分可为考虑使用177Lu-PSMA-617治疗的mCRPC患者提供有价值的预后信息。

研究设计与样本

  • 多中心回顾性研究,开发队列174例来自3个中心,用于构建多变量Cox模型并推导PROFILE评分,内部验证后在114例独立单中心队列中外部验证。

主要发现

  • 开发队列中PROFILE评分将患者分为3个风险组,Harrell C-index为0.67(95%CI 0.62-0.72)。
  • 开发队列低、中、高危组中位OS分别为17.2、13.0、8.6个月(P<0.0001)。
  • 验证队列中位OS分别为20.4、14.3、8.8个月(P<0.0001),C-index为0.73(95%CI 0.68-0.78)。

关键数值与推荐

  • PROFILE评分纳入5项独立不良预后因素:[18F]FDG PET/CT SUVmax超过PERCIST阈值300%、[68Ga]Ga-PSMA-11 PET/CT视觉PSMA肿瘤/唾液腺比值分类为「非高」、基线血红蛋白≤11 g/dL、基线碱性磷酸酶>220 IU/L、病程≤100个月。

临床怎么用

  • 在筛选177Lu-PSMA-617治疗资格的mCRPC患者时,可结合基线FDG与PSMA PET/CT及临床实验室参数计算PROFILE评分以辅助风险分层。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We investigated the prognostic value of baseline [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT in patients with metastatic castration-resistant prostate cancer treated with [177Lu]Lu-PSMA-617. Methods: In this multicenter retrospective study, the associations between several clinical, biologic, and radiologic parameters and overall survival (OS) were tested in a development cohort using univariable analyses, followed by the construction of a multivariable Cox model. The PROFILE prognostic score was subsequently derived from this model, internally validated, and externally validated in an independent cohort. Results: Data from 174 patients from 3 centers were used to construct the multivariable Cox model. Five independent adverse prognostic factors were identified and incorporated into the PROFILE score: an SUVmax exceeding 300% of the PERCIST threshold on [18F]FDG PET/CT, a "nonhigh" classification on [68Ga]Ga-PSMA-11 PET/CT using the visual PSMA tumor-to-salivary gland ratio, a baseline hemoglobin level of 11 g/dL or less, a baseline alkaline phosphatase level of greater than 220 IU/L, and a disease duration not exceeding 100 mo. The PROFILE score stratified patients into 3 risk groups and achieved a Harrell C-index of 0.67 (95% CI, 0.62-0.72). The median OS in the low-, intermediate-, and high-risk groups was 17.2, 13.0, and 8.6 mo, respectively (P < 0.0001). These results were confirmed in 114 patients in an independent, single-center validation cohort, with median OS of 20.4, 14.3, and 8.8 mo (P < 0.0001), respectively, and a C-index of 0.73 (95% CI, 0.68-0.78). Conclusion: The PROFILE score offers valuable prognostic information for patients with metastatic castration-resistant prostate cancer when considering the use of [177Lu]Lu-PSMA-617 therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jougla A, Nunes P, Giraudet AL, et al. Prognostic Value of a Composite Score Incorporating Baseline [18F]FDG PET/CT and [68Ga]Ga-PSMA-11 PET/CT When Screening for [177Lu]Lu-PSMA Treatment Eligibility (PROFILE Study). J Nucl Med. 2026. PMID: 42463288. doi:10.2967/jnumed.126.272368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。